Life sciences · Journal article
Molecular Cancer · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Extrachromosomal DNA (ecDNA) has emerged as a major contributor to cancer aggressiveness, yet its role extends far beyond its classical definition as a vehicle for oncogene amplification. Recent studies indicate that ecDNA functions as a dynamic regulatory platform that reshapes chromatin accessibility, enhancer activity, three-dimensional genome organization, nuclear architecture, and transcriptional output. Through these properties, ecDNA enables cancer cells to amplify oncogenic signaling, generate transcriptional plasticity, and rapidly adapt to selective pressures. In contrast to chromosomal amplification, ecDNA is structurally independent, frequently circular, acentromeric, and inherited through noncanonical mitotic behaviors, allowing unequal segregation, coordinated co-inheritance, and persistent propagation of advantageous regulatory states. Emerging evidence further shows that ecDNA can hijack pre-existing enhancers, rewire enhancer–oncogene communication, activate noncanonical regulatory elements, and assemble into transcriptionally active nuclear hubs and condensate-associated structures, thereby transforming genome rearrangement into epigenetic innovation. These mechanisms position ecDNA as a key driver of intratumoral heterogeneity, clonal evolution, metastatic adaptation, and therapeutic resistance. At the same time, the high transcriptional burden and specialized regulatory architecture of ecDNA-positive tumors may create selective vulnerabilities, including transcription–replication conflict and dependence on ecDNA-associated hubs, condensates, and regulatory modules. In this review, we synthesize current advances in the formation, regulation, inheritance, and functional consequences of ecDNA, with a particular focus on its emerging role as a platform for epigenetic reprogramming in cancer. We also discuss how this conceptual shift from copy-number biology to regulatory biology may redefine ecDNA as both a mechanistic framework for tumor plasticity and a potential frontier for precision oncology. ecDNA functions as more than an amplification vehicle and acts as a dynamic platform for epigenetic reprogramming in cancer. ecDNA reshapes oncogenic regulation through open chromatin states, enhancer rewiring, noncanonical regulatory activation, and nuclear hub formation. Noncanonical inheritance and spatially organized ecDNA assemblies drive intratumoral heterogeneity, clonal evolution, and therapeutic adaptation. ecDNA-associated transcriptional stress and regulatory architecture may expose new vulnerabilities for precision cancer therapy.